PDCL3P4

Across TCGA pan-cancer cohorts, PDCL3P4 RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of PDCL3P4’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where PDCL3P4 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types PDCL3P4 is over-expressed in tumor, although a few such as THCA and UCEC show the opposite, repressed pattern.

LIHC, THCA, and UCEC are the cancer types where PDCL3P4 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PDCL3P4 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Male	All	+0.532	<.001	8	view →
THCA	All	All	−0.591	<.001	7	view →
UCEC	All	All	−0.942	.005	6	view →
KICH	All	All	−0.973	<.001	5	view →
CHOL	Male	All	+1.411	.001	4	view →
BRCA	Female	All	−0.492	<.001	4	view →
STAD	All	All	+0.384	.036	2	view →
READ	Female	All	+1.022	.042	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

PDCL3P4–LIHC

Open the LIHC breakdown →